{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alectinib&page=2", "query": { "intervention": "Alectinib", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alectinib&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-22T15:21:39.343Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02091141", "title": "My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Solid Tumors", "Biliary Cancer", "Salivary Cancer", "Bladder Cancer" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 673, "start_date": "2014-04-14", "completion_date": "2023-05-24", "has_results": true, "last_update_posted_date": "2024-07-23", "last_synced_at": "2026-09-22T15:21:39.343Z", "location_count": 60, "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Springdale, Arkansas + 47 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Culver City", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02091141" }, { "nct_id": "NCT05384626", "title": "A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "Neladalkib (NVL-655)", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvalent Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 840, "start_date": "2022-06-09", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-09-22T15:21:39.343Z", "location_count": 21, "location_summary": "Orange, California • Sacramento, California • Stanford, California + 16 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05384626" }, { "nct_id": "NCT03596866", "title": "A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ALK+ Advanced NSCLC" ], "interventions": [ { "name": "Brigatinib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 248, "start_date": "2019-04-19", "completion_date": "2024-09-18", "has_results": true, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-09-22T15:21:39.343Z", "location_count": 4, "location_summary": "Whittier, California • Athens, Georgia • Albany, New York + 1 more", "locations": [ { "city": "Whittier", "state": "California" }, { "city": "Athens", "state": "Georgia" }, { "city": "Albany", "state": "New York" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03596866" }, { "nct_id": "NCT05987956", "title": "Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "ALK-Positive Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "ALECENSA - alectinib hydrochloride capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "24 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "24 Years to 64 Years" }, "enrollment_count": 600, "start_date": "2026-03-18", "completion_date": "2026-12-28", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-22T15:21:39.343Z", "location_count": 2, "location_summary": "Doral, Florida • Rockville, Maryland", "locations": [ { "city": "Doral", "state": "Florida" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05987956" }, { "nct_id": "NCT04774718", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "ALK Fusion-positive Solid or CNS Tumors" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "ALL", "summary": "Up to 17 Years" }, "enrollment_count": 42, "start_date": "2021-09-14", "completion_date": "2032-02-28", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-22T15:21:39.343Z", "location_count": 7, "location_summary": "Palo Alto, California • St. Petersburg, Florida • Ann Arbor, Michigan + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04774718" }, { "nct_id": "NCT02023125", "title": "A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" }, { "name": "Esomeprazole", "type": "DRUG" }, { "name": "High Fat and Calorie Meal", "type": "OTHER" }, { "name": "Standard Meal", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 42, "start_date": "2013-12", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2016-10-07", "last_synced_at": "2026-09-22T15:21:39.343Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02023125" }, { "nct_id": "NCT05987644", "title": "Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer", "NSCLC", "Brain Metastases" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Joshua Palmer", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2024-03-07", "completion_date": "2029-02-28", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-09-22T15:21:39.343Z", "location_count": 3, "location_summary": "Stanford, California • Aurora, Colorado • Columbus, Ohio", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05987644" }, { "nct_id": "NCT03546894", "title": "A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anaplastic Lymphoma Kinase-positive", "Carcinoma Non-small-cell Lung" ], "interventions": [ { "name": "Brigatinib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Ceritinib", "type": "DRUG" }, { "name": "Lorlatinib", "type": "DRUG" }, { "name": "Any FDA Approved ALK Inhibitors", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2018-07-23", "completion_date": "2023-02-13", "has_results": false, "last_update_posted_date": "2024-07-15", "last_synced_at": "2026-09-22T15:21:39.343Z", "location_count": 1, "location_summary": "Maynard, Massachusetts", "locations": [ { "city": "Maynard", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03546894" }, { "nct_id": "NCT02074553", "title": "A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "Ro542-4802/F03 (Reference)", "type": "DRUG" }, { "name": "Ro542-4802/F07 (Test)", "type": "DRUG" }, { "name": "Ro542-4802/F08 (Test)", "type": "DRUG" }, { "name": "Ro542-4802/F14 (Test)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 97, "start_date": "2014-02", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2023-12-11", "last_synced_at": "2026-09-22T15:21:39.343Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02074553" }, { "nct_id": "NCT03737994", "title": "Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Non-Squamous Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" }, { "name": "Brigatinib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ceritinib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Ensartinib", "type": "DRUG" }, { "name": "Lorlatinib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2019-07-25", "completion_date": "2026-03-17", "has_results": true, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-09-22T15:21:39.343Z", "location_count": 491, "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 341 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03737994" } ] }